page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Ranitadine (Zantac)

Category:

  • Gastrointestinal

Description:

  • Antiulcer agent (H2 antagonist)

Indications:

  • Duodenal ulcer; benign gastric ulcer

  • Pathological hypersecretory conditions (Zollinger-Ellison syndrome)

  • Gastroesophageal reflux disease (GERD)

  • Erosive gastritis

  • Stress ulcer prophylaxis

Drug Interactions:

  • Reduced efficacy: cefuroxine, cefpodoxime

  • Enhanced hypoglycemic effect: glipizide

  • Increased bioavailability: nifedipine, nitrendipine, nisoldipine

  • Decreased plasma concentrations: ketoconazole, enoxacin

Precautions:

  • Pregnancy category B; compatible with breast feeding

  • Stagger doses of ranitadine and antacids

Adverse Reactions (Side Effects):

  • CNS: dizziness, insomnia, malaise, somnolence, vertigo

  • CV: atrioventricular block, bradycardia, premature ventricular beats, tachycardia

  • GI: Abdominal discomfort or pain, constipation, hepatitis, increased liver function tests, nausea, vomiting, pancreatitis (rare)

  • HEME: granulocytopenia, leukopenia, thrombocytopenia

  • SKIN: alopecia, erythema multiforme (rare), rash

  • MS: arthralgias, myalgias

Dosage:

Administered PO (tablets, gelatin capsules, syrup), IV, and IM

  • Adult: 

    • Duodenal and gastric ulcer: PO 150mg twice daily or 300mg at bedtime for 4-8 weeks, maintenance 150mg every night at bedtime

    • GERD: 

      • PO 150mg twice daily

    • Erosive esophagitis: 

      • PO 150mg four times daily, maintenance 150mg twice daily

    • Pathological hypersecretory conditions: 

      • PO 150mg twice daily initially, titrate to desired response up to 6 grams daily

      • IV INF start 1mg/kg/hr, increase by 0.5mg/kg/hr intervals every 4 hours as needed up to 2.5mg/kg/hr

      • IM/IV 50mg every 6 to 8 hours, do not exceed 400mg per day; 

      • IV INF 6.25mg/hr

  • Child:

    • PO 1.25mg/kg every 12 hours, max 300mg/kg/day

    • IM/IV 0.75-1.5mg/kg every 6-8 hours, max 6mg/kg/day or 300mg/day

    • IV INF 0.1-0.25mg/kg/hr

 


The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

 

Advertise on this site